Dual Receptor Pharmacology Model: Optimizing GLP-1/Glucagon Agonism

Focus: The Ratio of GLP-1 to Glucagon Activity

The Dual Receptor Pharmacology Model is centered on elucidating the optimal pharmacological balance—often termed the "Golden Ratio"—between Glucagon-like Peptide 1 (GLP-1) and Glucagon receptor agonism. This model uses the investigational therapeutic Survodutide as its foundational example, analyzing how its unique receptor binding profile translates into therapeutic efficacy, specifically in metabolic health and weight management. The overarching goal is to define the characteristics of a peptide that achieves superior metabolic outcomes compared to single-agent therapies.

Product: Dual Receptor Pharmacology Model

This document outlines the scientific framework and core applications of the Dual Receptor Pharmacology Model, which is designed to guide the development and optimization of next-generation co-agonists. This model is not a physical product but a comprehensive theoretical and experimental blueprint for understanding the complex interplay between GLP-1 and Glucagon pathways when co-activated by a single molecular entity.

Scientific Background

The development of Survodutide represents a significant step in metabolic pharmacology, serving as a critical model for optimizing the in vivo effects of dual agonism. The following areas constitute the core scientific investigation within this model:

1. Balance: Optimizing the "Golden Ratio"

The concept of the "Golden Ratio" is paramount to this model. It investigates the precise balance of receptor activation required to maximize beneficial metabolic effects—primarily significant and sustained weight loss—while simultaneously minimizing undesirable side effects, such as gastrointestinal distress (e.g., nausea) or acute glycemic dysregulation (e.g., hyperglycemia).

This requires detailed kinetic analysis:

• GLP-1 Dominance: Primarily drives improved glucose tolerance and appetite suppression. An over-reliance may lead to more pronounced gastrointestinal side effects.
• Glucagon Dominance: Primarily drives energy expenditure and lipolysis (fat breakdown). An over-reliance may lead to transient, undesirable increases in blood glucose levels.

The Dual Receptor Pharmacology Model utilizes comparative analysis of peptides with varying GLP-1/Glucagon ratios to map the dose-response curve for both efficacy (weight loss) and tolerability (adverse events).

2. Desensitization and Internalization Dynamics

Chronic exposure to high-affinity agonists can lead to receptor desensitization and internalization, reducing the long-term effectiveness of the therapeutic. The model studies the receptor internalization dynamics specifically under chronic dual-agonist exposure, which may differ significantly from single-receptor agonism.

• Receptor Kinetics: Detailed study of the rate of receptor internalization for both GLP-1R and GCGR when simultaneously bound by Survodutide.
• Signal Bias: Investigation into whether the dual agonist preferentially activates specific downstream signaling pathways (e.g., cAMP vs. β-arrestin recruitment), and how this bias may mitigate desensitization.
• Mitigation Strategies: Identifying specific structural characteristics of the peptide that favor recycling over degradation of the receptors, thus preserving responsiveness during long-term treatment.

Receptor Type

Acute Agonism Response

Chronic Dual-Agonism Kinetics

Potential Impact on Efficacy

GLP-1 Receptor (GLP-1R)

Glucose-dependent insulin secretion

Internalization rate and recycling efficiency

Sustained glycemic control and appetite suppression

Glucagon Receptor (GCGR)

Hepatic glucose output, energy expenditure

Changes in surface expression and degradation rates

Long-term increase in energy expenditure and weight loss

3. Substrate Utilization and Energy Metabolism Shift

A critical hypothesis of dual agonism is that the Glucagon component, by increasing energy expenditure and promoting lipolysis, shifts the body’s fuel preference. The model explores how the peptide influences the body's substrate utilization, specifically examining the shift from carbohydrate oxidation to fat oxidation.

Key Metabolic Assessments

• Respiratory Exchange Ratio (RER): Measuring RER in vivo to quantify the proportion of energy derived from carbohydrates versus fats. A reduction in RER indicates a beneficial shift toward fat oxidation.
• Hepatic Lipid Content: Assessing the effect of the dual agonist on reducing ectopic fat accumulation, particularly in the liver (relevant to MASH/NASH). The Glucagon component is thought to be critical for this effect.
• Mitochondrial Function: Studying the impact of GCGR activation on mitochondrial biogenesis and oxidative capacity in key metabolic tissues (muscle, adipose tissue).

Page 2

Structural Pharmacology Considerations

The Survodutide molecule is a single peptide designed to engage two distinct G-protein coupled receptors (GPCRs). This section details the structural considerations vital to achieving the desired "Golden Ratio."

A. Molecular Design and Affinity

The design must ensure adequate affinity for both the GLP-1R and GCGR to achieve the therapeutic effect at a clinically relevant dose. Differential affinity, where the peptide binds to one receptor with higher potency than the other, is one mechanism used to achieve the desired activity ratio.

Feature

GLP-1R Affinity

GCGR Affinity

Rationale

Native Peptide

High

Moderate

Basic reference

Survodutide

High

Moderate-High (Optimized)

Designed to balance glucose control with energy expenditure

Person Analog

Person

Low

Hypothesized for reduced side effects

B. Peptide Stability and Pharmacokinetics

The therapeutic efficacy of a dual agonist is heavily reliant on its prolonged half-life, allowing for once-weekly or less frequent dosing.

• Protease Resistance: Modifications to the peptide backbone (e.g., N-terminal protection) to resist cleavage by Dipeptidyl Peptidase-4 (DPP-4) are crucial.
• Albumin Binding: Incorporation of a lipophilic moiety (e.g., a fatty acid chain) to enable reversible binding to serum albumin. This dramatically extends the half-life.

The Dual Receptor Pharmacology Model includes pharmacokinetic (PK) studies to correlate the in vivo exposure levels of the peptide with the sustained activation levels of both receptors.

Page 3

Usage: Experimental Applications

The Dual Receptor Pharmacology Model is an essential tool for both early-stage discovery and late-stage pre-clinical development. Its primary applications are in standardized in vitro receptor binding assays and in vivo pharmacokinetic/pharmacodynamic (PK/PD) studies.

A. In Vitro Receptor Binding and Functional Assays

These assays are the cornerstone for defining the actual GLP-1/Glucagon activity ratio of a peptide.

1. Receptor Binding Affinity ($\text{K}_{\text{i}}$):

• Method: Competitive binding assays using radiolabeled ligands (e.g., $\text{I}^{125}$-Exendin-4 for GLP-1R and $\text{I}^{125}$-Glucagon for GCGR) on cells expressing the human receptors.
• Purpose: To determine the equilibrium dissociation constant ($\text{K}_{\text{i}}$) of Survodutide for both receptors, establishing the affinity ratio.

1. Functional Potency ($\text{EC}_{50}$):

• Method: Measuring intracellular cAMP production (the canonical second messenger) in response to the dual agonist.
• Purpose: To determine the half-maximal effective concentration ($\text{EC}{50}$) for activation of each receptor, establishing the functional activity ratio. This value is more relevant than $\text{K}{\text{i}}$ for predicting in vivo effects.

The following table summarizes the data generated from the receptor binding assays.

Assay Type

Target Receptor

Standard Agonist ($\text{EC}_{50}$)

Survodutide ($\text{EC}_{50}$)

Functional Ratio (GLP-1R:GCGR)

cAMP Production

GLP-1R

File

File

cAMP Production

GCGR

File

File

[A chart showing the receptor binding affinity and functional potency of Survodutide across GLP-1R and GCGR]

B. Pharmacokinetic (PK) Studies

These studies determine the fate of the peptide in a living system, linking its structural design to its exposure profile.

• Absorption, Distribution, Metabolism, Excretion (ADME): Standard non-clinical models (e.g., rodent, non-human primate) are used to track the peptide concentration in plasma and tissues over time.
• Target Engagement: Using specialized probes or techniques to confirm that the peptide reaches and binds to the target receptors in vivo.

Page 4

The GLP-1 Component: Efficacy and Safety Modulation

The GLP-1 component of Survodutide is primarily responsible for the glucose-lowering and appetite-suppressing effects. The model investigates how the co-activation of the Glucagon receptor may modulate both the efficacy and side effect profile of the GLP-1 activity.

Efficacy Enhancement

• Insulin Secretion: While GLP-1 is a potent secretagogue, the glucagon component, if balanced, can subtly influence this. The model tests whether the overall energy deficit induced by glucagon allows GLP-1 to operate more efficiently over the long term.
• Appetite Suppression: GLP-1 acts centrally on the hypothalamus. GCGR activation also has central effects, potentially leading to synergistic or additive suppression of food intake.

Side Effect Mitigation

The most common side effects of GLP-1-dominant therapies are gastrointestinal (nausea, vomiting).

• Nausea Mechanism: The model hypothesizes that the metabolic improvements driven by the GCGR component (e.g., less reliance on carbohydrate stores) may indirectly reduce the gastrointestinal distress often linked to rapid changes in gastric emptying or central signaling.
• Titration Strategy: The ratio derived from this model dictates the optimal starting dose and titration schedule for the molecule, minimizing adverse events during the initial treatment phase. This informs clinical trial design, such as the timing of the next dosage increase at a clinical trial visit at Place on Date.

Page 5

The Glucagon Component: Metabolic Reprogramming

The Glucagon component is key to distinguishing dual agonists from simple GLP-1 agonists. While native Glucagon raises blood glucose, the balanced co-agonism aims to harness its catabolic and energy-expenditure properties while mitigating its hyperglycemic effect.

A. Thermogenesis and Energy Expenditure

GCGR activation leads to an increase in basal metabolic rate (BMR), often linked to effects on brown adipose tissue (BAT) and the liver.

• BAT Activation: The model uses imaging and molecular markers to confirm Glucagon-mediated thermogenesis in BAT, leading to increased caloric burn.
• Adipose Tissue Remodeling: Promoting the "browning" of white adipose tissue (WAT) into more metabolically active beige adipocytes, thereby increasing overall energy dissipation.

B. Hepatic and Lipid Metabolism

Glucagon’s role in the liver is complex. While it drives hepatic glucose output, it also promotes the breakdown of fat (lipolysis).

• Lipolysis and VLDL Regulation: Studies focus on the peptide’s ability to promote fat breakdown in adipose tissue, leading to free fatty acid (FFA) release, which are then preferentially metabolized by the liver. The net effect is the clearance of ectopic fat (e.g., liver fat) without causing a persistent, undesirable increase in VLDL (very-low-density lipoprotein) production.
• MASH/NASH Relevance: The strong effect of the Glucagon component on reducing hepatic steatosis is critical for potential applications in Metabolic Dysfunction-Associated Steatohepatitis (MASH). A follow-up meeting is scheduled to discuss these findings with Person at Calendar event.

Page 6

Regulatory and Manufacturing Implications

The dual receptor pharmacology model has direct implications for regulatory submissions and manufacturing scale-up, as the precise ratio is a critical quality attribute (CQA).

Quality Control of the Active Pharmaceutical Ingredient (API)

Maintaining the correct GLP-1 to Glucagon activity ratio is essential for batch consistency.

• Bioassay Development: Developing robust, high-throughput bioassays based on the functional $\text{EC}_{50}$ data (as defined in Page 3) to release manufacturing batches. Any deviation in the functional ratio would necessitate batch rejection or further purification.
• Structural Integrity: Using techniques such as Mass Spectrometry and High-Performance Liquid Chromatography (HPLC) to confirm the primary and secondary structure of Survodutide, ensuring no modifications have occurred that would alter its dual binding capacity.

Pre-Clinical Toxicology

The model guides the design of toxicology studies, focusing on potential safety margins for the GCGR component.

• Dose Range Finding: Defining the maximum tolerated dose (MTD) based on both GLP-1-related adverse effects (e.g., nausea) and GCGR-related effects (e.g., transient elevations in heart rate or glucose).
• Off-Target Effects: Screening for binding to other related GPCRs (e.g., GIPR, Calcitonin Receptor) to confirm high selectivity.

Page 7

Modeling and Simulation: Predicting the Golden Ratio

Computational modeling is a core element of the Dual Receptor Pharmacology Model, used to predict in vivo efficacy based on in vitro data.

A. Quantitative Systems Pharmacology (QSP)

QSP models integrate molecular kinetics with physiological responses to simulate the effects of Survodutide across different organ systems.

• Integration Points:
• Input: $\text{EC}_{50}$ ratio (from in vitro assays) and human PK data.
• Model Components: Subsystems for the gastrointestinal tract, pancreas, liver, adipose tissue, and central nervous system (CNS).
• Output: Simulated body weight loss, change in $\text{HbA}_{1\text{c}}$, and predicted adverse event frequency.

This simulation allows researchers to virtually test thousands of hypothetical dual-agonist ratios before synthesizing a single new molecule, significantly accelerating the discovery process.

B. Predicting Long-Term Efficacy

The QSP model helps predict the sustainability of the weight loss and metabolic improvements over 1-2 years, accounting for receptor desensitization and physiological adaptation (e.g., the body's natural compensatory mechanisms against weight loss). A detailed report on the QSP findings is available at File.

Page 8

Future Directions and Next-Generation Agonists

The insights derived from the Survodutide model are intended to inform the development of tri-agonists (e.g., GLP-1/Glucagon/GIP) and other complex multi-receptor peptides.

Beyond the "Golden Ratio"

The model will be extended to define the optimal pharmacological landscape for triple agonism.

• GIPR Integration: Investigating how the inclusion of Glucose-dependent Insulinotropic Polypeptide Receptor (GIPR) agonism modulates the GLP-1/Glucagon ratio effects, particularly regarding bone health and energy storage dynamics.
• Tissue Selectivity: Designing peptides that show preferential activity at receptors in specific tissues (e.g., liver-targeting Glucagon agonism to maximize fat breakdown while minimizing systemic glucose elevation).

Personalized Medicine

In the long term, the model suggests a path toward personalized dual agonism.

• Genotype-Phenotype Correlation: Identifying genetic markers (polymorphisms) in GLP-1R or GCGR that influence a patient's response to a specific ratio.
• Ratio Titration: Developing a framework where the GLP-1/Glucagon ratio of the therapeutic is adjusted based on a patient's dominant metabolic phenotype (e.g., a patient with severe hepatic steatosis may benefit from a more Glucagon-dominant ratio).

Page 9

Model Deliverables and Documentation

The final outputs of the Dual Receptor Pharmacology Model are comprehensive reports and validated experimental protocols designed for research teams and regulatory agencies.

Deliverable

Description

Target Audience

Date of Completion

Receptor Activation Profile Report

Comprehensive $\text{K}{\text{i}}$ and $\text{EC}{50}$ data, defining the precise functional ratio of Survodutide.

Discovery Chemistry, Regulatory Affairs

Date

PK/PD Correlation Study

Report linking plasma concentration to in vivo weight loss, energy expenditure, and glucose control.

Pre-Clinical Development

Date

QSP Simulation Report

Predictions of long-term efficacy and tolerability for various dosing regimens and ratios.

Clinical Development

Date

SOP: Receptor Binding Assay

Step-by-step protocol for high-throughput screening of new dual agonist candidates at Place.

Assay Development Team

Date

Page 10

Summary of the Dual Receptor Principle

The Dual Receptor Pharmacology Model, using Survodutide as a template, confirms that the co-agonism of GLP-1 and Glucagon is a highly effective strategy for treating metabolic disease, but its success is entirely dependent on achieving the optimal balance.

The GLP-1 component provides foundational effects:

• Glucose control and insulin sensitization
• Satiety and reduced food intake

The Glucagon component provides the synergistic lift:

• Increased energy expenditure (thermogenesis)
• Promotion of fat oxidation and clearance of ectopic fat

By systematically investigating the three scientific pillars—Balance, Desensitization, and Substrate Utilization—this model provides the necessary framework to design superior metabolic therapeutics with optimized efficacy and minimized side effects. The results from this model will directly inform the next stage of clinical trials planned for Date at the Place research facility.